Bausch Health Companies Inc. (TSX: BHC)

Canada flag Canada · Delayed Price · Currency is CAD
10.74
-0.03 (-0.28%)
Jan 30, 2025, 11:57 AM EST
-2.45%
Market Cap 3.97B
Revenue (ttm) 12.80B
Net Income (ttm) -240.47M
Shares Out n/a
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 49,973
Average Volume 203,399
Open 10.80
Previous Close 10.77
Day's Range 10.65 - 10.88
52-Week Range 5.45 - 15.43
Beta 0.75
RSI 47.67
Earnings Date Feb 20, 2025

About Bausch Health Companies

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in... [Read more]

Sector Healthcare
CEO Thomas Appio
Employees 20,270
Stock Exchange Toronto Stock Exchange
Ticker Symbol BHC
Full Company Profile

Financial Performance

In 2023, Bausch Health Companies's revenue was $8.76 billion, an increase of 7.79% compared to the previous year's $8.12 billion. Losses were -$592.00 million, 163.1% more than in 2022.

Financial numbers in USD Financial Statements

News

Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025

LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, Febr...

7 days ago - Accesswire

Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conferen...

7 days ago - Accesswire

Bausch Health Swaps Out Advisers After Years of Debt, Sale Talks

Executives at Bausch Health Cos Inc are shaking up the company’s team of advisers as part of the latest in a years-long effort to tackle some of its approximately $20 billion dollars of debt and enabl...

7 days ago - BNN Bloomberg

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarte...

8 days ago - Business Wire

Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for...

13 days ago - Accesswire

Bausch + Lomb CEO on the negative impact of screen time on eye health

Brent Saunders, Bausch and Lomb CEO, discusses how too much screen time can have a negative impact on vision.

15 days ago - CNBC Television

Bausch and Lomb CEO: Right on track with our important initiatives

Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more.

16 days ago - CNBC Television

Bausch and Lomb CEO: Right on track with our important initiatives

Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more.

16 days ago - CNBC

George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America

George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America

17 days ago - GlobeNewsWire

Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate h...

17 days ago - Business Wire

Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial...

17 days ago - Business Wire

InflammX Therapeutics Announces Option Agreement with Bausch + Lomb

TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet...

20 days ago - GlobeNewsWire

Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine

JERSEY CITY, N.J.--(BUSINESS WIRE)--Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health ...

20 days ago - Business Wire

City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced that it has entered...

20 days ago - Business Wire

Outcome Capital Congratulates Elios Vision on the Acquisition by Bausch + Lomb

BOSTON--(BUSINESS WIRE)--Outcome's expertise in corporate strategy, financing, and transaction execution helped position ELIOS as a key innovator in glaucoma treatment market.

21 days ago - Business Wire

Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundati...

23 days ago - Business Wire

Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman ...

4 weeks ago - Business Wire

Contact lens maker Bausch + Lomb says it is exploring sale

Bausch + Lomb is exploring a potential sale among other options, it said on Thursday, in a move that would help Canadian parent Bausch Health exit the eye-care company.

6 weeks ago - Reuters

Bausch & Lomb edges higher after confirming sales process

Bausch & Lomb (BLCO) confirms sales process for eyecare company, exploring potential sale options as part of full separation from Bausch Health Companies...

7 weeks ago - Seeking Alpha

Bausch Health Companies Inc (BHC) Responds to Potential Sale Rumors

Bausch Health Companies Inc (BHC) Responds to Potential Sale Rumors

7 weeks ago - GuruFocus

Bausch + Lomb Responds to Rumors of a Potential Sale

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following statement...

7 weeks ago - Business Wire

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a...

7 weeks ago - Accesswire

Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 50 points on Wednesday.

7 weeks ago - Benzinga

Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affili...

7 weeks ago - Business Wire